Table of contents
In this issue
p871 | doi:10.1038/nrd2745
Editorial: Tackling the clinical value conundrum
p873 | doi:10.1038/nrd2746
News and Analysis
Pathways to cancer therapy | PDF (193 KB)
p875 | doi:10.1038/nrd2748
Payers growing influence on R&D decision making | PDF (149 KB)
p876 | doi:10.1038/nrd2749
News in Brief
Biobusiness Briefs
Deal watch: GSK acquires rights to Valeant's anti-epileptic drug | PDF (121 KB)
p880 | doi:10.1038/nrd2752
Trial watch: Novel biologic for psoriasis shows superiority over current best-seller | PDF (116 KB)
p880 | doi:10.1038/nrd2753
Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products | PDF (111 KB)
p881 | doi:10.1038/nrd2754
Patent watch
Injunction keeps Mircera off the US market | Selecting from chemical classes | NF-
B patent dispute moves to Appeals Court | Na+/K-ATPase modulators | PDF
(272 KB)
p882 | doi:10.1038/nrd2751
An Audience With
Ray Woosley | PDF (129 KB)
p884 | doi:10.1038/nrd2732
The President of the Critical Path Institute discusses the successes to date and future challenges of helping the FDA to improve the process for developing safe, innovative drugs.
From the analyst's couch
A decade of the Fast Track programme | PDF (213 KB)
p885 | doi:10.1038/nrd2733
Fresh from the Pipeline
Romiplostim | PDF (256 KB)
p887 | doi:10.1038/nrd2741
Research Highlights
Neurodegenerative disease: New ways of tackling A
toxicity | PDF
(149 KB)
p889 | doi:10.1038/nrd2738
Lung injury: Promoting fluid clearance | PDF (136 KB)
p890 | doi:10.1038/nrd2737
Atherosclerosis: Preventing plaque rupture | PDF (142 KB)
p890 | doi:10.1038/nrd2739
Antibacterial drugs: New paths to beating bacteria | PDF (145 KB)
p891 | doi:10.1038/nrd2735
Cardiovascular disease: Enhanced protection of the heart | PDF (141 KB)
p892 | doi:10.1038/nrd2736
In brief
Viral diseases | Cancer | Diabetes | Anticancer drugs | PDF (145 KB)
p892 | doi:10.1038/nrd2740
Perspectives
Article series: A guide to drug discovery
Opinion
Typical pitfalls in applications for marketing authorization of biotechnological products in Europe
Christian K. Schneider & Gabriele Schäffner-Dallmann
p893 | doi:10.1038/nrd2728
Despite improvements in European regulatory standards and procedures, the occurrence of failed or problematic marketing authorization applications for biotechnological products remains common. Here, Schäffner-Dallmann and Schneider identify common regulatory concerns and consider strategies that may help prevent such issues.
Innovation
Genomic-scale prioritization of drug targets: the TDR Targets database
Fernán Agüero, Bissan Al-Lazikani, Martin Aslett, Matthew Berriman, Frederick S. Buckner, Robert K. Campbell, Santiago Carmona, Ian M. Carruthers, A. W. Edith Chan, Feng Chen, Gregory J. Crowther, Maria A. Doyle, Christiane Hertz-Fowler, Andrew L. Hopkins, Gregg McAllister, Solomon Nwaka, John P. Overington, Arnab Pain, Gaia V. Paolini, Ursula Pieper, Stuart A. Ralph, Aaron Riechers, David S. Roos, Andrej Sali, Dhanasekaran Shanmugam, Takashi Suzuki, Wesley C. Van Voorhis & Christophe L. M. J. Verlinde
p900 | doi:10.1038/nrd2684
The wealth of genomic data for pathogens that cause tropical diseases hold considerable promise for the discovery of novel drugs. An international consortium describes how the TDR Targets database integrates this data with related biochemical and pharmacological data to facilitate the identification and prioritization of drug targets.
Reviews
Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary
Rocio S. Lopez-Diego & Howard L. Weiner
p909 | doi:10.1038/nrd2358
Novel immunomodulatory agents have considerably improved the treatment of multiple sclerosis in recent years, but inhibiting disease progression remains a central challenge. This article describes how advances in the understanding of the immunopathogenesis of multiple sclerosis have identified a range of novel targets for intervention and potential therapeutic agents acting at various steps in the pathogenic cascade, including different aspects of T-cell and B-cell function and neuroprotective strategies.
Novel therapeutic applications of cardiac glycosides
Ioannis Prassas & Eleftherios P. Diamandis
p926 | doi:10.1038/nrd2682
Cardiac glycosides, a diverse family of naturally derived compounds that inhibit Na+/K+-ATPase, have been used for many years for the treatment of heart failure and atrial arrhythmia. This article discusses recent evidence highlighting additional signal transduction roles for Na+/K+-ATPase, and associated potential new therapeutic appplications for glycoside-based drugs in a range of diseases — most notably cancer, for which the first generation of such agents are currently in clinical trials.
Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection
Norberto Perico, Ariela Benigni & Giuseppe Remuzzi
p936 | doi:10.1038/nrd2685
With no specific cures for most acquired chronic kidney diseases, current efforts are focused on preventing disease progression. Here, Remuzzi and colleagues discuss examples of novel drugs and biologics that might be used to target the inflammatory and profibrotic process, and glomerular injury, highlighting results from recent clinical trials.
